Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab plus MG4101 in Relapsed/Refractory Indolent CD20+ NHL
NCT03578198Phase 2Terminated
- Sponsor
- Seoul National University Hospital
- Start
- Nov 2018
- Primary completion
- Apr 2022
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
A Phase 2 trial of MG4101 in Indolent Non-Hodgkin Lymphoma (INHL), sponsored by Seoul National University Hospital. Started Nov 2018; status: terminated.
02
Drugs
MG4101
03
Conditions
Indolent Non-Hodgkin Lymphoma (INHL)
Beyond the preview
Go deeper on NCT03578198.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03578198.